Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Philippe Chatellard is active.

Publication


Featured researches published by Philippe Chatellard.


Journal of Biotechnology | 2001

Development of stable cell lines for production or regulated expression using matrix attachment regions

Monique Zahn-Zabal; Michel Kobr; Pierre-Alain Girod; Markus Imhof; Philippe Chatellard; Maria De Jesus; Florian M. Wurm; Nicolas Mermod

One of the major hurdles of isolating stable, inducible or constitutive high-level producer cell lines is the time-consuming selection procedure. Given the variation in the expression levels of the same construct in individual clones, hundreds of clones must be isolated and tested to identify one or more with the desired characteristics. Various boundary elements (BEs), matrix attachment regions, and locus control regions (LCRs) were screened for their ability to augment the expression of heterologous genes in Chinese hamster ovary (CHO) cells. Of the chromatin elements assayed, the chicken lysozyme matrix-attachment region (MAR) was the only element to significantly increase stable reporter expression. We found that the use of the MAR increases the proportion of high-producing clones, thus reducing the number of clones that need to be screened. These benefits are observed both for constructs with MARs flanking the transgene expression cassette, as well as when constructs are co-transfected with the MAR on a separate plasmid. Moreover, the MAR was co-transfected with a multicomponent regulatable beta-galactosidase expression system in C2C12 cells and several clones exhibiting regulated expression were identified. Hence, MARs are useful in the development of stable cell lines for production or regulated expression.


Journal of Gene Medicine | 2000

A regulatory network for the efficient control of transgene expression.

Markus Imhof; Philippe Chatellard; Nicolas Mermod

Expression of heterologous genes in mammalian cells or organisms for therapeutic or experimental purposes often requires tight control of transgene expression. Specifically, the following criteria should be met: no background gene activity in the off‐state, high gene expression in the on‐state, regulated expression over an extended period, and multiple switching between on‐ and off‐states.


Journal of Biotechnology | 2002

Comparative study and identification of potent eukaryotic transcriptional repressors in gene switch systems.

Markus Imhof; Philippe Chatellard; Nicolas Mermod

In mammalian cells, proper gene regulation is achieved by the complex interplay of transcription factors that activate or repress gene expression by binding to the regulatory regions of target promoters. While transcriptional activators have been extensively characterised and classified into functional groups, relatively little is known about the comparative strength and cell type-specificity of transcriptional repressors. Here, we have compared the ability of a series of eukaryotic repression domains to silence basal and activated transcription. A series of the most potent repression domains was further tested in the context of a gene therapy gene-switch system in various cell types. The results indicate that the analysed repression domains exert varying silencing activities in different promoter contexts. Furthermore, their potential for gene silencing varies also depending on the cellular context. When multimerised within one chimeric repressor protein, particular combinations of repressor domains were found to display synergistic repressing effects and efficient repression in a panel of cell lines. This approach thus allowed the identification of transcriptional repressors that are both potent and versatile in terms of cellular specificity as a basis for gene switch systems.


Biotechnology and Bioengineering | 2001

Transient gene expression: Recombinant protein production with suspension-adapted HEK293-EBNA cells

Petra Meissner; Horst Pick; Alexandra Kulangara; Philippe Chatellard; Kirstin Friedrich; Florian M. Wurm


Archive | 2002

Matrix attachment regions and methods for use thereof

Nicolas Mermod; Monique Zahn-Zabal; Markus Imhof; Philippe Chatellard; Pierre-Alain Girod


Biotechnology and Bioengineering | 2007

The IE2 promoter/enhancer region from mouse CMV provides high levels of therapeutic protein expression in mammalian cells.

Philippe Chatellard; Renata Pankiewicz; Evelyne Meier; Laurence Durrer; Christophe Sauvage; Markus Imhof


Archive | 1999

Potent genetic switch allowing regulated gene expression in eukaryotic cells

Nicolas Mermod; Markus Imhof; Philippe Chatellard


BioProcessing Journal | 2008

Expression Vector Engineering for Cell Line Development - New Roles for "Old" Sequences

Markus Imhof; Michel Kobr; Philippe Chatellard


Archive | 2008

IFN-beta sencillo fusionado a un fragmento Fc de lgG mutado

Peter Hjelmstrom; Markus Imhof; George Feger; Nigel Jenkins; Philippe Dupraz; Christine A. Power; Laurent Magnenat; Philippe Chatellard; Renata Pankiewicz; Vincent Dechavanne; Gian Battista Bozzato


Archive | 2008

IFN-beta fused to a single Fc fragment of IgG mutated

Peter Hjelmstrom; Markus Imhof; George Feger; Nigel Jenkins; Philippe Dupraz; Christine A. Power; Laurent Magnenat; Philippe Chatellard; Renata Pankiewicz; Vincent Dechavanne; Gian Battista Bozzato

Collaboration


Dive into the Philippe Chatellard's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge